Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors
June 18 2015 - 4:01PM
Business Wire
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
announced that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of
directors as an independent director. Dr. Bhatia was elected to
serve a three-year term ending in 2018.
"Dr. Bhatia is a leading physician scientist and medical
researcher who brings a wealth of expertise to our board," said
Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief
Executive Officer of Vertex. “Her extensive experience in the field
of biomedical engineering and in-depth understanding on the use of
advanced technologies in medical research will provide valuable
insights to our board and our company as we advance key research
and development programs.”
Dr. Bhatia is a physician and engineer and has been a professor
at the Massachusetts Institute of Technology (MIT) since 2005. She
currently serves as the John J. and Dorothy Wilson Professor of
Health Sciences at the MIT Institute for Medical Engineering and
Science and Electrical Engineering and Computer Science (EECS). She
also currently serves as a Biomedical Engineer in the Department of
Medicine for Brigham and Women’s Hospital, an investigator for the
Howard Hughes Medical Institute, a member of the Koch Institute for
Integrative Cancer Research at MIT and a member of the Broad
Institute. She recently received the Heinz Award for Technology,
the Economy, and Employment from the Heinz Family Foundation and
the Lemelson-MIT Prize for her dedication to STEM education and to
improving human health through technological innovations. From 1998
to 2005, Dr. Bhatia was a professor of bioengineering and medicine
at the University of California at San Diego. Dr. Bhatia holds a
B.S. in Biomedical Engineering from Brown University, an M.S. in
Mechanical Engineering and Ph.D. in Biomedical Engineering from
MIT, and an M.D. from Harvard Medical School.
“I believe Vertex has a unique opportunity to integrate new
medical technologies into its research and development programs in
cystic fibrosis and other diseases in the years ahead,” said Dr.
Bhatia. “I look forward to providing my insights as both a
physician and scientist to Vertex’s board at this exciting
time.”
About Vertex
Vertex is a global biotechnology company that aims to discover,
develop and commercialize innovative medicines so people with
serious diseases can lead better lives. In addition to our clinical
development programs focused on cystic fibrosis, Vertex has more
than a dozen ongoing research programs aimed at other serious and
life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has
research and development sites and commercial offices in the
United States, Europe, Canada and Australia. For
five years in a row, Science magazine has named Vertex
one of its Top Employers in the life sciences. For additional
information and the latest updates from the company, please
visit www.vrtx.com.
(VRTX-GEN)
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150618006295/en/
Vertex Pharmaceuticals IncorporatedInvestors:Michael Partridge,
617-341-6108orMedia:Zach Barber, 617-341-6470MediaInfo@vrtx.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From May 2023 to May 2024